重庆华森制药股份有限公司投资者关系活动记录表 证券代码：002907 证券简称：华森制药 编号：2021-005 | --- | --- | --- | |--------------------|-----------------------------------------------------|--------------------------------------------------------| | | | | | | □特定对象调研 | □分析师会议 | | | ■媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | 参与单位名称及 | 财联社 张海霞 | | | 人员姓名 | | | | 时间 | 2021 年 12 月 27 日 | | | 地点 | 通过电话会议方式进行 游雪丹（副总经理、董事会秘书） | | | 上市公司接待人姓名 | 葛 磊（证券事务代表） | | | | | 一、公司在遵守信息披露制度的前提下，介绍公司经营业 | | | | | | | 公告内容一致。 | 绩、产 ...

重庆华森制药股份有限公司投资者关系活动记录表 证券代码：002907 证券简称：华森制药 编号：2021-004 | --- | --- | --- | |--------------------|-------------------------------------------------------------------|------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n□其他 | □分析师会议 \n□业绩说明会 \n□路演活动 | | 参与单位名称及人员 | 量桥投资管理（上海）有限公司 | 高级合伙人 黄元贺 | | 姓名 | 上海淳阳私募基金管理有限公司 | 董事长、投资总监 谢伟玉 | | | 西南证券股份有限公司 | 投资银行部 张锴 | | 时间 | 2021 年 11 月 30 日 | | | 地点 | 公司 3 楼会议室 | | | 上市公司接待人姓名 | | 游雪丹（副总经理、董事会秘书） | | | 葛 磊（证 ...

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------------| | 投资者关系活动类别 | ■特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n□其他 | □分析师会议 \n□业绩说明会 \n□路演活动 | | 参与单位名称及 人员姓名 | 民生证券股份有限公司 | 研究院分析师 宋丽莹 | | 时间 | 2022 年 1 月 14 日 | | | 地点 | | 公司三楼会议室（游雪丹女士通过电话会议方式参会） | | 上市公司接待人姓名 | 游雪丹（副总经理、董事会秘书） | | | | 葛 磊（证券事务代表） | 一、公司在遵守信息披露制度的前提下，介绍公司经营业 ...

Group 1: Company Strategy and Development - The company will focus on high-quality development and innovation-driven strategies, targeting areas such as oncology, immunology, and metabolism over the next 3-5 years [1] - The construction of the innovative drug sector is the core development direction for the next decade, with plans to enhance R&D capabilities to rank among the top in China [2] - The company aims to establish a pipeline with over 2 innovative drug clinical approvals and 3 clinical candidate compounds during the 14th Five-Year Plan [2] Group 2: Product Development and Market Strategy - The company has built three major innovative drug technology platforms and aims to expand its product pipeline with a target of launching at least six new products annually [3] - In the field of special medical foods, the company plans to leverage its pharmaceutical advantages to become the first in Chongqing to launch a full range of special nutritional products [3][7] - The company is actively exploring digital marketing and multi-channel development to enhance market share and product promotion [2] Group 3: Financial Performance and Challenges - The company reported a 9.87% year-on-year increase in revenue when excluding the decline in sales of a partnered product [4] - The five exclusive traditional Chinese medicine products showed a 19.72% increase in sales revenue [4] - Operating profit decreased by 24.83% and net profit decreased by 22.99% due to increased R&D investments and reduced government subsidies [4][5] Group 4: Market Conditions and Future Outlook - The company acknowledges the impact of external factors such as the pandemic and market fluctuations on stock prices, emphasizing a commitment to stable operations and compliance [3][5] - The company is preparing for potential entry into traditional Chinese medicine procurement, which is expected to expand in the future [5] - The company maintains a healthy cash flow and does not foresee liquidity risks, ensuring support for ongoing R&D activities [6]

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |--------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n□其他 | □分析师会议 \n□业绩说明会 \n□路演活动 | | 参与单位名称及 | 德邦证券 高远 | | | 人员姓名 | 德邦证券 王绍玲 翊安（上海）投资有限公司 | 赵汉辉 等 | | 时间 | 2022 年 5 月 7 日 | | | 地点 | 公司二楼会议室（电话会议） | | | 上市公司接待人姓名 | 游雪丹（副总经理、董事会秘书） 周智如（证券及法务总监 ...

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司投资者关系活动记录表 编号：2022-006 | --- | --- | --- | |--------------------|--------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n 媒体采访 \n□新闻发布会 \n□现场参观 \n□其他 | □分析师会议 \n□业绩说明会 \n□路演活动 | | 参与单位名称及 | 21 世纪经济报 秦凡 | | | 人员姓名 | 21 世纪经济报 周洋 | | | 时间 | 2022 年 6 月 7 日 | | | 地点 | 公司二楼会议室 | | | 上市公司接待人姓名 | | 游雪丹（董事、副总经理、董事会秘书） | | | 周智如（证券及法务总监） | | ...

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司投资者关系活动记录表 编号：2022-007 | --- | --- | --- | |-----------------------------|--------------------------------------|-----------------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | | 媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | | 广发证券范卓宇、董远 | | | | 银华基金 孙慧、张雨 | | | | 国寿安保 曲朗宁 | | | 参与单位名称及 | 信银理财 李赛 | | | 人员姓名 | 中国建设银行资管部 | 李军 | | | 宁银理财 韦婉 | | | | 华宝基金 孙嘉伦 | | | | 方正证券固收部 ...

Group 1: Company Development Strategy - The company will continue to focus on high-quality development and innovation-driven strategies, leveraging its three main advantages: digestive, ENT, and neuropsychiatry fields, while expanding into cancer, immunity, respiratory, and metabolic disease areas [1] - The construction of the innovative drug sector is the core development direction for the next decade, with increased investment in this area [2] Group 2: R&D and Product Pipeline - The company aims to enhance its innovative drug R&D capabilities to rank among the top in China during the 14th Five-Year Plan, targeting over 2 clinical approvals and 3 clinical candidate compounds with global intellectual property rights [2] - The company has established a "333" pipeline structure for generic drugs, aiming for at least 6 projects to be initiated, filed, and approved for market each year in the future [2] Group 3: Market Strategy and Sales Channels - The company maintains a strong presence in public hospitals, with a sales ratio of approximately 8:2 between public and non-hospital markets, while focusing on expanding the outpatient market [3] - The company has covered nearly 9,500 public hospitals across 31 provinces, cities, and autonomous regions in China [3] Group 4: Financial Expectations and Revenue Impact - The company anticipates that the steady growth of its proprietary traditional Chinese medicine sector will offset current revenue and profit impacts, with plans for 2-3 new product launches annually [3] - The company expects to receive its first special medical food production license within 3 years, positively impacting revenue and cash flow [5] Group 5: Innovation and Clinical Progress - The company has 4 self-developed innovative drug projects in preclinical stages targeting various cancers, with some projects showing promising data and expected to enter IND-Enabling research by the end of the year [4] - The company is focusing on developing special medical foods, with two projects already underway, including nutritional supplements for post-surgery recovery [4]

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司 投资者关系活动记录表 编号：2022-009 | --- | --- | --- | --- | |-------------------------|-----------------------------------------|----------------------------|--------------------------------------------------------------------------------------------------------------------| | | | | | | | □特定对象调研 □媒体采访 | □分析师会议 ■业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | 参与单位名称及 人员姓名 | 通过"路演中"网络平台参与公司 会的投资者 | 2022 | 年半年度网上业绩说明 | | 时间 | 2022 年 9 月 1 日 | | | ...

证券代码：002907 证券简称：华森制药 重庆华森制药股份有限公司投资者关系活动记录表 编号：2022-010 | --- | --- | --- | |-------------------------|-------------------------------|----------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | | 媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | □其他 | | | | 信达证券 | 张弛、王明路；前海人寿 黄皓；浙商证券 金豪； | | | 平安基金 | 江正青；中金资管 莫华寅、樊荣；建信基金 李峰； | | 参与单位名称及 人员姓名 | 国联证券 | 高远，安柯，黄荣达，赵润笛；信达澳亚 王宇豪； | | | 英大资产 | 刘青青；天弘基金 刘佳欣； 通过"路演中"平台参加调研活动的若干投资者 | | | 2022 年 10 月 28 日 | 1 ...